Aeterna Zentaris names new CEO and considers options for the firm

21 July 2017

The share price of Canada-based Aeterna Zentaris’ (TSX: AEZS) had shot up by nearly 200% to $3.01 by Friday lunchtime compared to Tuesday’s close, with the company considering what to do following some good news.

This news was the acceptance by the US Food and Drug Administration (FDA) of the company’s New Drug Application seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults, as a complete response to the FDA’s November 2014 Complete Response Letter. The agency granted a PDUFA date of December 30, 2017.

Aeterna announced on Thursday that it had formed a special committee of independent directors – the strategic review committee – to consider and evaluate various strategic and financing alternatives available to the company to maximize shareholder value, including continuing to execute on its existing business plan or considering and recommending changes to management and governance.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK